A recent AJKD article by Kitrungphaiboon et al explored whether cefepime monotherapy, as an empirical treatment of CAPD-associated peritonitis, has noninferior efficacy for the resolution of peritonitis at day 10 (primary treatment response) compared to the conventional combination regimen of cefazolin plus ceftazidime.

AJKD’s Social Media Editor, Timothy Yau @Maximal_Change, recorded an interview with his ID colleagues, Gerome Escota @MDdreamchaser and Andrej Spec @FungalDoc, to learn more about this issue:

If the embedded player doesn’t work, please click here to listen to the audio interview.

Dr Spec is head of@WU_Mycoses and Dr Escota is one of the leaders of @WuidQ. Special thanks to both of them for agreeing to do the interview! 

To view this article, please visit AJKD.org.

Intraperitoneal Cefepime Monotherapy Versus Combination Therapy of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-Associated Peritonitis: A Multicenter, Open-Label, Noninferiority, Randomized, Controlled Trial by Thidarat Kitrungphaiboon et al  

DOI: 10.1053/j.ajkd.2019.05.011

Editorial Cefepime as Empirical Peritoneal Dialysis–Associated Peritonitis Treatment: Something to Dwell On? by Muthana Al Sahlawi et al [FREE]